Form 4: Zevra Therapeutics' Chief Medical Officer Receives Stock Options and Restricted Stock Units

Adrian W. Quartel, Chief Medical Officer of Zevra Therapeutics, was granted stock options and restricted stock units on January 30, 2025, according to a Form 4 filing.

Summary

• Adrian W. Quartel, the Chief Medical Officer of Zevra Therapeutics, received stock options and restricted stock units on January 30, 2025.
• The stock option grants him the right to buy 68,000 shares of Zevra Therapeutics stock at an exercise price of $8.02 per share.
• These options vest in four equal annual installments starting January 29, 2026, contingent upon his continued service.
• The options will fully vest upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.
• The options expire ten years after the grant date.
• He also received 34,000 restricted stock units (RSUs), each representing a contingent right to receive one share of Zevra's common stock.
• One third of the RSUs will vest on January 30, 2026, with the remaining two thirds vesting in equal annual installments thereafter, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance and the executive's role in it.

Positives

• The grants of stock options and restricted stock units align the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Granting stock options and restricted stock units is a common practice in the pharmaceutical industry to incentivize key executives and align their interests with the company's long-term success. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biopharmaceutical industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options and RSUs to incentivize their leadership teams.
• The vesting schedules described are fairly standard, with annual vesting over a 3-4 year period being common.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's performance.
• Employees may see this as a positive sign of investment in leadership and the company's future.

Key Dates

Keywords

ZEVRA THERAPEUTICS, ZVRA, stock options, restricted stock units, Form 4, insider trading, Adrian W. Quartel, Chief Medical Officer, equity incentive plan, vesting